Please login to the form below
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization.
Welcome to Delta – the new Fishawack Health magazine.
We’ve chosen to focus our first edition of the magazine on a topic close to our hearts, rare diseases.
Rare diseases represent an incredibly high unmet need, not only due to the lack of therapies and the practical difficulties in diagnosis, but also in patients’ desire for better knowledge, communication, and more meaningful relationships with their healthcare professionals.
As our rare disease specialist agency Dudnyk says: “We are seeing a growing separation between healthcare professionals and patients. The impact of this great divide in understanding is negatively affecting the treatment experience—for both sides—as well as severely limiting the trajectory of specialty healthcare brands.”
The dynamic between patients and healthcare professionals, combined with the challenges of patient identification and data generation in tiny patient populations (made even more challenging in a global pandemic), means rare disease drug development and launch requires a unique business model.
In this edition of Delta, our consultants, creatives and medical communications experts explore the challenges and opportunities for life science companies operating in rare disease, including:
- Navigating real-world evidence and why it could be a gamechanger in rare disease
- A patient’s account of living with a rare disease in the COVID-19 pandemic
- How to make an impact in small patient populations
- The lessons Dan Zaksas, PhD, Senior Vice President, Director of Scientific and Medical Affairs at Dudnyk, has learned during a decade working in rare diseases
- Why you need to build relationships with KOLs and patients much earlier than you think
- The lasting implications of COVID-19 on the life science industry.
Company Details
Fishawack Health
Address:
No. 3 Booths Park
Booths Hall
Chelford Road
Knutsford
Cheshire
WA16 8GS
United Kingdom
Latest content on this profile
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Fishawack Health
- Why it’s time to apply a payer lens to your early pipeline planning
- Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
- The fast-paced future of cell and gene therapies
- In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health
- Omnichannel scientific engagement and the use of archetypes to drive personalization
- Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can use archetypes to segment their audience and develop personalized learning journeys for healthcare professionals.
Fishawack Health
- The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
- With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.
Fishawack Health
- Report: Reinventing product and portfolio value for the biopharmaceutical industry
- Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of stakeholders earlier than you think.
Fishawack Health
